Elmiron, also known as pentosan polysulfate sodium, has been shown to be toxic to the retina and causing permanent damage, called Pigmentary Maculopathy. Studies have shown that up to 25% of patients with “significant exposure to Elmiron” have shown signs of eye damage. If found early, the damage can be treated and potentially reversed, if found too late, damage may result in permanent vision loss.
To learn more, read the FDA’s announcement here https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.
Known as the CAMELLIA-TIMI 61 trial, this was the largest cardiovascular outcome trial conducted to date for a weight loss medication. Through this study, it was found that Belviq increases the user’s chance of contracting cancer. On February 13, 2020, the FDA’s Drug Safety Communication advises patients to stop taking Belviq immediately due to health risks. To learn more, visit https://www.belviq.com/ or read the FDA’s report here https://www.fda.gov/media/135189/download.
● Dimming of Vision
● Sudden Vision Blurring
● Difficulty Seeing Objects up Close
● Difficulty Adjusting to Brightness and Darkness
● Sudden Blind Spots in your Field of Vision